Fractional Flow Reserve Market Report 2023 (Global Edition)

Top Companies Market Share in Fractional Flow Reserve Industry: (In no particular order of Rank)

• Abbott Laboratories; Boston Scientific; ACIST Medical Systems; Koninklijke Philips N.V.; Opsens
• Inc.; HeartFlow
• Inc.; Siemens Healthineers; Pie Medical Imaging; CathWorks; Opsens Medical.
• Confidential Data
• Access The Paid Version
• Data Hidden

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..

Competitive Analysis of the Fractional Flow Reserve market

The companies are investing in different products and services to expand their portfolio. For instance, FDA has approved Abbott's new FFR Coronary Lesion Assessment Technology. Abbott's intravascular Resting Full-cycle Ratio (RFR) test is a newer type of fractional flow reserve (FFR) physiologic measurement. RFR is used to help identify substantial coronary artery narrowing in order to assess whether a stent is needed or if a patient may be treated medically.

Recent News- Fractional Flow Reserve Market

• June 2022- Siemens Healthineers announces the Artis icono biplane, which features detectors built specifically for cardiovascular care.

Artis icono biplane provides for straightforward positioning of the C-arm for complex cardiovascular illnesses and interventional treatment, especially when displaying pictures at steep angulations. Furthermore, photos from several perspectives can be captured at the same time. This saves time and has the potential to result in a lower contrast agent dose for patients. Artis icono biplane offers a novel sort of X-ray exposure management that takes contrast-to-noise ratios into account to maintain the same high degree of image quality regardless of patient size or angulation1. As a result, clinicians and patients benefit from high image quality at a minimal radiation dose.

• July 2021- HeartFlow, the Precision Heart Care Leader, has announced a merger with Longview Acquisition Corp. II to become a publicly traded company. 

HeartFlow's artificial intelligence-enabled software platform transforms the way heart disease is diagnosed and treated, bringing precision heart care to cardiology. The HeartFlow Analysis is the first and only non-invasive instrument to aid in the diagnosis, management, and treatment of individuals suffering from heart disease, the most common kind of cardiovascular illness that accounts for one in every three fatalities and one out of every six dollars spent on healthcare in the United States. HeartFlow has been shown to have higher diagnostic accuracy than other non-invasive tests, with an 83% reduction in needless invasive angiograms, resulting in a significant reduction in total cost of treatment.

Research Methodology Implemented by Author

• 1.1 Fractional Flow Reserve Market Report 2023 Research Methodology
• 1.2 Systematic Research Approach
  • 1.2.1 Primary Research for Fractional Flow Reserve Market
  • 1.2.1.1 Key Data from Primary
  • 1.2.1.2 Primary Interviews with Experts
  • 1.2.1.3 Key Industry Insights
  • 1.2.1.4 Questionnaire for Fractional Flow Reserve Market
  • 1.2.1.5 Breakdown of Primaries
  • 1.2.2 Secondary Research for Fractional Flow Reserve Market
  • 1.2.2.1 Key Data from Secondary
  • 1.2.2.2 Paid Sources
  • 1.2.2.3 Public Sources
• 1.3 Market Size Estimation for Fractional Flow Reserve Market
  • 1.3.1 Top-Down Approach
    • 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
  • 1.3.2 Bottom-UP Approach
    • 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
• 1.4 Market Breakdown and Data Triangulation
• 1.5 Research Assumptions for Fractional Flow Reserve Market